Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study

被引：0
|
作者：
Bai, Xueli
Chen, Yiwen
Zhang, Junlei
Hu, Wendi
Li, Xiang
Shen, Yan
Zhang, Min
Wu, Jian
Gao, Shunliang
Yu, Jun
Que, Risheng
Zhang, Yun
Yang, Fuchun
Xia, Weiliang
Zhang, Aibin
Tang, Xiaofeng
Liang, Tingbo
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4108
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study-The CISLD-12 study.
    Liang, Tingbo
    Chen, Yiwen
    Huang, Xin
    Hu, Wendi
    Li, Xiang
    Sun, Junhui
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Yu, Jun
    Que, Risheng
    Zhang, Yun
    Yang, Fuchun
    Xia, Weiliang
    Zhang, Aibin
    Tang, Xiaofeng
    Bai, Xueli
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 558 - 558
  • [2] Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study
    Jiang, Yi
    Su, Ke
    Li, Han
    Wang, Chenjie
    Wu, Zhenying
    Chen, Jiali
    Zhang, Zhiyao
    He, Kun
    Han, Yunwei
    INVESTIGATIONAL NEW DRUGS, 2025, 43 (01) : 18 - 29
  • [3] The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.
    Yang, Xin-Rong
    Cheng, Jian-Wen
    Wu, Suiyi
    Hu, Bo
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study
    Chen, Yiwen
    Zhang, Junlei
    Hu, Wendi
    Li, Xiang
    Sun, Ke
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Yu, Jun
    Que, Risheng
    Zhang, Yun
    Yang, Fuchun
    Xia, Weiliang
    Zhang, Aibin
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [5] Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
    Li, Dailong
    Xu, Lu
    Ji, Jinxing
    Bao, Dan
    Hu, Juan
    Qian, Ying
    Zhou, Yinjie
    Chen, Zhuo
    Li, Daojun
    Li, Xiaopeng
    Zhang, Xiaoling
    Wang, Hao
    Yi, Changjun
    Shi, Menglu
    Pang, Yaqi
    Liu, Siqi
    Xu, Xinhua
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] A single-arm, prospective study on the efficacy and safety of TACE-HAIC combined with lenvatinib and tislelizumab in the treatment of unresectable hepatocellular carcinoma.
    Zhu, Jun
    Feng, Xu
    Duan, Jintao
    Fu, Yu
    Liang, Jie
    Peng, Mi
    Zhu, Zimo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
    Xu, Yongkang
    Fu, Shumin
    Mao, Ye
    Yi, Fengming
    Jiang, Weiming
    Feng, Long
    Wu, Jianbing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 500 - 500
  • [8] Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
    Shao, Guoliang
    Zeng, Hui
    Zhang, Zhewei
    Luo, Jun
    Zhang, Dinghu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 499 - 499
  • [9] Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study
    Li Yanwei
    Feng, He
    Ren, Peng
    Yue, Jie
    Zhang, Wencheng
    Tang, Peng
    Shang, Xiaobin
    Pang, Qingsong
    Liu, Dongying
    Chen, Chuangui
    Pan, Zhanyu
    Tao, Yu Zhen
    ONCOLOGIST, 2020, 25 (10): : E1464 - E1472
  • [10] Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study)
    Kuang, Ming
    Xu, Lixia
    Zhang, Mengping
    Zheng, Gaomin
    Zhang, Chuankai
    Zhang, Ying
    Su, Tianhong
    Wang, Jifei
    Wang, Fang
    Wang, Fengjie
    Chen, Huanwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345